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INTRODUCTION 
Cardiovascular disease (CVD) is a kind of diseases that deals with 
the heart or blood vessels.[1] Cardiovascular disease involves coronary artery 
diseases (CAD) such as angina and myocardial infarction (commonly certified as 
heart attack).[1]  Other CVDs are stroke, hypertensive heart disease, rheumatic heart 
disease, cardiomyopathy, heart arrhythmia, congenital heart disease, aortic 
aneurysms, peripheral artery disease, valvular heart disease and venous 
thrombosis.[1],[2] Globally cardiovascular diseases are the major and main cause of 
death.[1] In 2013 17.3 million deaths (31.5%) were cropped up from 12.3 million 
(25.8%) in 1990.[2] Deaths from Cardiovascular disease at a given age are more 
habitual and have been expanding in much of the developing world, while rates have 
been dropped in developing countries since the 1970s.[3],[4] 80% of Cardiovascular 
disease deaths in male and 75% in female were scored for stroke and Coronary 
artery disease.[1] Most CVD’s affects older adults.  
11% of people in US in the age of 20 to 40 having CVD, while in the range 
of 40 to 60 years are 37% of people, 71% of citizens between 60 and 80 have CVD, 
and people over 80 are 85%.[5]In the developed world the approximate age of death 
from coronary artery disease is around 80 while it is around 68 in the developing 
countries.[4] Disease access is commonly 7 to 10 years earlier in men than women.[6] 
EPIDEMIOLOGY: 
CVDs are the headmost cause of death. In 2008, 30% of all worldwide 
deaths is indicated to cardiovascular diseases.  
Death aimed by CVD’s are also greater in low as well as middle-income 
countries as over 80% of loss of life caused by cardiovascular diseases globally 
occurred in those countries. It is also predicted that, over 23 million people will be 
expired from cardiovascular diseases each year by 2030. Approximately 60% of the 
burden of cardiovascular disease in the world will occur in the South Asian 
subcontinent even though they make up 20% of the world's population. This may be 
the result of a combination of environment and genetic predisposition factors.  
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Organizations such as the Indian Heart Association are working with 
the World Heart Federation to raise awareness about this issue.[7]  
TYPES: 
There are numerous cardiovascular diseases involving the blood vessels. They are known 
as vascular diseases:  
 Coronary artery disease (also known as coronary heart disease and ischemic 
heart disease).  
 Peripheral arterial disease – disease of blood vessels that provide blood to the 
legs and arms.  
 Cerebrovascular disease – disease of blood vessels that provide blood to the 
brain (includes stroke). 
 Renal artery stenosis. 
 Aortic aneurysm. 
There are also various cardiovascular diseases that concern the heart.  
 Cardiomyopathy – diseases of cardiac muscle. 
  Hypertensive heart disease – diseases of the heart along with high blood 
pressure or hypertension. 
  Heart failure. 
  Pulmonary heart disease – a failure at the right side of the heart secondary to 
respiratory system involvement. 
 Cardiac dysrhythmias – irregular heart rhythm Inflammatory heart disease. 
 Endocarditis – inflammation of the inner layer of the heart, the endocardium. 
The most commonly involved structures are the heart valves.  
 Inflammatory cardiomegaly. 
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 Myocarditis – inflammation of the myocardium, the muscle of the heart. 
 Valvular heart disease. 
  Congenital heart disease – heart composition malformations existing at birth. 
  Rheumatic heart disease –valves and heart muscles destroyed due to rheumatic 
fever caused by Streptococcus pyogenes a group A streptococcal infection.[8]  
RISK FACTORS: 
There are several risk factors for heart diseases: age, sex, tobacco use, excessive 
alcohol consumption, physical inactivity, unhealthy diet, obesity, family history of 
cardiovascular disease, elevation of blood pressure (hypertension), elevated blood 
sugar (diabetes mellitus), hyperlipidemia (high blood cholesterol), poverty and low 
educational status, psychosocial factors and air pollution.[9],[10],[11],[12],[13] The 
individual contribution of these risk factors varies between different communities or 
ethnic groups while the overall contribution of each risk factor is very consistent .[14] 
Some of these risk factors, like sex, age or family history, genetic, are immutable; 
while other cardiovascular risk factors are adapted by social change, lifestyle 
change, drug treatment and prevention of hypertension, hyperlipidemia, and 
diabetes.  
 Modifiable risk factors: 
 Hypertension: 
Hypertension is the major hugest risk factor for stroke. It also undergoes an 
important role in heart attacks. It may be arrested and successfully cured but 
only if it has been diagnosed and stick to your recommended management 
plan.[15] 
 Cholesterol: 
Deviation of lipid levels in blood, known as high total cholesterol, elevation of 
triglycerides levels, high levels of low-density lipoprotein or low levels of high 
density lipoprotein (HDL) cholesterol all enlarged the heart disease and stroke 
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risks. Following a healthy diet, exercise and medication can improve your blood 
lipid profile.[15] 
 Diabetes: 
Type 2 diabetes an extreme coronary heart disease and stroke risks factor. 
Having diabetes doubles the likelihood of somebody who does not to develop 
cardiovascular disease. Developing cardiovascular disease at an earlier age than 
other people will be more likely, diabetes is not controlled and it will be more 
devastating. Diabetes emit out the protective effect of estrogen in per-
menopausal women and heart disease risks rises significantly.[15] 
 Tobacco: 
Tobacco: Using tobacco either by smoking or chewing to, improve risks of 
cardiovascular disease. The risk is increased especially if smoking started at 
young age, smoking heavily or was in woman. On other hand passive smoking is 
another risk factor for cardiovascular disease. Avoiding tobacco may decrease 
risk of cardiovascular disease.[15]  
 Diet: 
Low dietary consumption of fruits, vegetables, fish, high consumption of salt, 
saturated fat and trans-fats are linked to cardiovascular risk. It has been 
characterized by the World Health Organization that around 1.7 million deaths 
worldwide due to low fruit and vegetable consumption.[1] It is an important 
determinant of blood pressure levels and overall cardiovascular risk to measure 
the quantity of consumed dietary salt.[1] Frequent intake of high-calorie foods, 
such as processed foods that are high in sugars and fats, cause obesity and may 
improve cardiovascular risk.[1] High trans-fat intake has adverse effects on blood 
lipids and circulating inflammatory signs,[16] and trans-fat rejection across the 
border of diets has been widely advocated.[17] There is a fact that greater 
consumption of sugar is coupled with higher blood pressure and critical blood 
lipids,[18] and intake of sugar also augments the risk of diabetes mellitus.[19] 
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Great intake of processed meats is linked with elevation of cardiovascular 
disease risks, perhaps due to increased dietary salt intake.[20]  
 Alcohol consumption: 
The relationship between cardiovascular disease and alcohol consumption is 
multifaceted, and can depend on the quantity of alcohol consumed. There is a 
direct correlation between cardiovascular disease risks and high levels of alcohol 
consumption.[1] Drinking at low levels without incidence of heavy drinking may 
be linked with decreasing risk of cardiovascular disease.[21] Generally, alcohol 
consumption is linked with the level of population with multiple health risks that 
go beyond any potential benefits.[1],[22] 
 Physical inactivity: 
Lack of physical activity (defined as below 5 x 30 minutes of normal activity per 
week, or below 3 x 20 minutes of vigorous activity per week) is the fourth risk 
factor of death worldwide.[1] In 2008, around 31.3% of adults aged 15 or above 
(28.2% men and 34.4% women) were inadequate physically active.[1] The 
ischemic heart disease and diabetes mellitus risk is decreased by almost a third in 
adults who join in 150 minutes of moderate physical activity each week (or 
equivalent).[23] Apart from that, physical activity collaborates loss of weight and 
emends blood pressure, lipid profile, blood glucose control and insulin 
sensitivity. These effects may partially explain its cardiovascular benefits.[1] 
 Socioeconomic disadvantage: 
Cardiovascular disease influence in high-income countries less than low and 
middle-income countries.[24] There is comparatively little information about 
social patterns of cardiovascular disease within low- and middle-income 
countries,[24] but within high-income countries low educational status low 
income are typically linked with superior risk of cardiovascular disease.[25] The 
policies which resulted in increased socio-economic inequalities accompanied by 
greater socio-economic differences in cardiovascular disease[24] later on resulting 
in a domino effect relationship. Psychosocial considerations, environmental 
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exhibitions, health behaviors, and health-care, quality contribute and access to 
socio-economic differentials in cardiovascular disease.[26] The Commission on 
Social Determinants of Health recommended that more equal distributions of 
power, wealth, education, housing, environmental factors, nutrition, and health 
care were required to address inequalities in cardiovascular disease and non-
communicable diseases.[27]  
 Medications: 
Risk of heart disease may be elevated by medicines like contraceptive pill and 
hormone replacement therapy (HRT).[15]  
 Non modifiable risk factors: 
 Genetics: 
Cardiovascular disease in a person's parents increases their risk by 3 fold.[28] 
 Age: 
Age, so far is the most critical risk factor with approximately a tripling of risk 
with each decade of life in developing cardiovascular or heart diseases.[29] 
Coronary fatty streaks can start to form in adolescence.[30] It is considered that 
82 percent of citizens who die of coronary heart disease are 65 and older.[31] In 
the meanwhile, after age 55 the risk of stroke doubles every decade.[32] Several 
explanations have been proposed to clarify why age elevates the risk of 
cardiovascular/heart diseases such as serum cholesterol level.[33] In most 
individuals, the serum total cholesterol level elevates as age augments. In men, 
around the age 45 to 50 years this levels increases.  
In women, the increase continues sharply until age 60 to 65 years.[33] Aging is 
also collaborate with changes in the structural and mechanical properties of the 
vascular wall, which results in decreased arterial compliance and loss of arterial 
elasticity and may eventually cause coronary artery disease.[34]  
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 Sex: 
Male are at greater risk of heart disease than pre-menopausal female.[29][15] When 
exceeding menopause, it has been suggested that a female's risk is similar to a 
male's[15] recently facts from the World Health Organization and United Nation 
disputes this.[29] Diabetes in female make them more likely to promote heart 
disease than a male with diabetes.[35] Coronary heart diseases are more familiar 
among middle-aged men two to five times than women.[33] In a research done by 
WHO, gender contributes to nearly 40% of the variation in sex ratios of coronary 
heart disease mortality.[36] Another study concludes similar results finding that 
gender diversities explains almost half of the risk related to cardiovascular 
diseases[33] hormonal difference is one of the projected clarifications for sex 
differences in cardiovascular diseases.[33] By the whole of women, estrogen is 
the absolute sex hormone.  
Estrogen may have guarding property through glucose metabolism and 
haemostatic system, and may have direct effect in promoting endothelial cell 
function.[33] The creation of estrogen diminishes after menopause, and this may 
alter the female lipid metabolism to more atherogenic form by reducing the HDL 
cholesterol level while increasing total cholesterol and LDL levels.[33] There are 
notable differences in height, body weight, heart rate, body fat distribution, 
arterial compliance and stroke volume among male and female.[34] At a very 
early age, pulsatility and hardening of arteries significantly associated with age 
is more obvious among female than male.[34] This might be due to the women's 
smaller body size and arterial dimensions which are independent of 
menopause.[34] 
 Ethnicity: 
Your ethnic origin plays a role. Asian or African origin are at higher risks of 
creating cardiovascular disease than other racial groups.[15] 
TREATMENTS: 
There are various classes of medications prescribed for heart disease patients. It's 
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essential for both care givers and patients suffered from heart disease to understand 
the prescribed medication, to follow the directions of usage, and to be capable to 
know the obtainable side effects associated with the medicine. The most common 
prescribed drugs for heart disease include:[37] 
 ANGIOTENSIN CONVERTING ENZYME(ACE) INHIBITORS: 
Angiotensin is a hormone that forces the blood vessels to narrow or get smaller. 
This increases individual’s blood pressure. By decreasing the level of angiotensin, 
blood vessels enlarge. Blood flows easier through the enlarged blood vessels and 
blood pressure are reduced. A doctor would prescribe an ACE inhibitor for people 
with hypertension or heart failure because the heart doesn’t draft sufficient blood to 
fit the body’s demands.[38] They also block fragment of the harmful procedures of 
the endocrine system that might occur with heart failure.[37] These medications are 
also vital post-heart attack. This is because they can help prevent a future event and 
they also help to recover the heart muscle from the insufficiency of oxygen during 
the heart attack.[38]Examples for commonly prescribed drugs includes: 
- Benazepril.  - Captopril. - Enalapril. 
- Fosinopril. - Lisinopril. - Moexipril. 
- Perindopril. - Quinapril. - Ramipril. 
- Trandolapril.[39]    
 ANGIOTENSIN-II RECEPTOR BLOCKERS (ARB): 
Unlike angiotensin converting enzyme inhibitors, angiotensin receptor 
blockers completely block the effects of angiotensin II on the heart. This effect 
lowers blood pressure. Doctors prescribe this medication to CHF patients and 
patients with hypertension. Angiotensin receptor blockers and angiotensin 
converting enzyme inhibitors have related functions and purposes. Studies have 
shown ACE inhibitors may slow kidney disease improvement in type 1 diabetes and 
kidney disease patients. ARBs may slow kidney disease improvement in type 2 
diabetes and kidney disease patients.[40] Examples for frequently prescribed drugs 
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includes: 
-Candesartan - Eprosartan - Irbesartan 
-Losartan  - Telmisartan - Valsartan[39] 
 ANTICOAGULANTS (BLOOD THINNERS): 
Plaque is a primary problems in coronary artery disease. Sometimes it can 
cause blood clots. Clot partially or completely prevent blood from flowing anywhere 
past the clot, when the clot lodged in a heart vessel. Any heart muscle that relied on 
that vessel for nutrients and oxygen will die if blood flow is not build up very 
quickly. A potentially fatal pulmonary embolism can result, when blood clot moves 
to the lungs. Stroke could occur, when a clot lodges in the brain. Anticoagulants can 
block blood clots from forming but don’t break up existing blood clots.[41] Examples 
for frequent prescribed drugs includes: 
-Rivaroxaban -  Dabigatran -  Apixaban 
- Heparin  -  Warfarin[39] 
 ANTIPLATELETS: 
Antiplatelet medications are prescribed after a cardiac event like a heart 
attack. Doctors also prescribe them for people with known plaque developed in their 
arteries to prevent heart attacks. People who experience abnormal heart rhythms, 
such like atrial fibrillation may also take antiplatelets because they are at increased 
risk for blood clots.[41]Examples for frequent prescribed drugs includes: 
- Aspirin - Clopidogrel -Dipyridamole 
-Prasugrel -  Ticagrelor[39]  
 BETA BLOCKERS: 
Beta-blockers block the effects of adrenaline (epinephrine) and thereby 
enhance the heart's ability to perform. They also decrease the production of harmful 
substances creates by the body in response to heart failure. They cause the heart 
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pulse rate to be more gently with quite force, lowering blood pressure.[37] Examples 
for frequent prescribed drugs includes: 
- Acebutolol - Atenolol  - Bisoprolol 
- BetaxololBisoprolol/hydrochlorothiazide     
- Metoprolol - Nadolol - Propranolol  
- Sotalol[39] 
 CALCIUM CHANNEL BLOCKERS (CCB): 
Calcium channel blockers can work on different regions of the body to serve 
specific purposes based on a person’s unique health condition or conditions. 
Calcium has several effects on the body such as trigger heart contractions. By 
reducing calcium’s rate in triggering these contractions, blood vessels can relax. 
Blood pressure then lowers. Doctors prescribe CCBs for hypertension, heart 
arrhythmias and chest pain patients.[41]Examples for frequent prescribed drugs 
includes: 
- Amlodipine  - Diltiazem - Felodipine 
- Nifedipine - Nimodipine - Nisoldipine 
- Verapamil[39] 
 CHOLESTEROL LOWERING MEDICATION: 
Cholesterol formed in the blood vessels may cause plaque to build up, 
narrowing blood vessels. The plaque can break off and block the blood vessel if a 
blood clot forms around the plaque rupture. Examples of cholesterol-lowering 
medications include the following. It has been proven that some of these drugs 
decrease the risk of death from CAD: 
 Statins: Atorvastatin, Pravastatin sodium and Simvastatin. 
 Bile acid resins: Cholestyramine 
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 Cholesterol absorption inhibitors: Ezetimibe    
 Fibric acid derivatives: Fenofibrate 
 Nicotinic acid: Niacin[41] 
 VASODILATORS: 
Vasodilators prescribed to cure heart failure and manage elevated blood 
pressure by comforting the blood vessels so blood can flow smoothly through the 
body. Vasodilators are selected for patients who cannot take ACE inhibitors.[37] 
Examples for frequent prescribed drugs includes:  
-Isosorbidedinitrate - Nesiritide -Hydralazine  
-Nitrates - Minoxidil 
 DIURETICS: 
Diuretics, generally known as “water pills,” allow the kidneys to get rid of 
unneeded salt and water from the bloodstream and tissues into the urine. Getting rid 
of plenty of fluid makes it simple for your heart to pump. Diuretics are prescribed to 
treat elevated blood pressure and reduce the swelling and water build-up caused by 
various medical problems, including heart failure. They also helps make breathing 
easier.[37] Examples for frequent prescribed drugs includes: 
- Amiloride - Bumetanide - Chlorothiazide 
-Chlorthalidone - Furosemide  - Hydrochlorothiazide 
-Indapamide - Spironolactone [39] 
DRUD PRESCRIPTION PATTERN: 
Prescribing pattern are a reflection of the ability of health professionals to 
distinguish among the various choices of drugs and determine the ones that will 
most benefit their patients.[42] Prescription writing is an art and science, as it 
forwards the message from the physician to the patient. Prescription order is an 
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important harmony among the physician and the patient. It is an order for a scientific 
medication for a member at a particular time.[43]It brings in to focus on discerning 
diagnosis and therapeutic efficiency for the physician with instructions for softening 
or restoration of the patient’s health.[44] The study of prescribing patterns described a 
part of medical review and seeks to monitor, evaluate if necessary, propose 
amendments in prescribing practices to make medical care rational and cost 
effective.[45] Apposite drug utilization studies are essential means to review whether 
drugs are utilized accurately in terms of effectiveness, security, expediency and 
financial aspects at all stages in the series of drug use.[46] 
DRUG UTILIZATION: 
Drug utilization research is an important branch of pharmacoepidemiology as 
it elucidate the scope, character and determinants of drug exposure.[47]the world 
health organization (WHO)in 1997 defined drug utilization as the prescribing, 
allotment, marketing and use of drugs in a civilization , among a particular focus on 
the medical, social, and economic consequence resulted.[48] Drug use is a complex 
process. In any country a large number of socio-cultural factors assign to the manner 
in which drugs are used. In India, these includes national drug policy, illiteracy, 
poverty, use of multiple health care systems, drug marketing and promotion, sale of 
prescription drugs without prescription, competition in the medical and 
pharmaceutical market place and limited availability of independent, unbiased drug 
information. The complexity of use of drug means the optimal profits of drug 
therapy in patient care may not be attained because of underuse, overuse or abuse of 
drugs. Unfortunate drug use might also cause to elevate rate of medical concerns, 
antimicrobial resistance, adverse effects and patient mortality.[49] Hence 
contemporary studies on drug utilization have developed into a probable mean to be 
used in the assessment of health systems.[50]The awareness of drug utilization studies 
starts in the early 1960s. [51,52] and its importance has elevated since then because of 
augmentation in marketing of new drugs, deep distinction in the pattern of drug 
prescribing and utilization, rising concern about delayed adverse events and the 
mounting concern regarding the charge of drugs.[53,54,55,56] 
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TYPES OF DRUG UTILIZATION STUDIES: 
Drug Utilization studies are moreover Qualitative or Quantitative [49]  
 Qualitative Drug Utilization studies are multidisciplinary process which 
collect, organize, analyze and report information an actual drug use. They 
usually examine use of precise drugs or specific conditions.  
 Quantitative Drug Utilization studies involve the collection, organization, 
and demonstration of estimates or measurements of drug use. This 
information is generally used for making purchase decisions or preparing 
drug budgets. However statistics from quantitative drug utilization studies 
are generally considered suggestive, indefinite with respects to quality of 
drug use.  
SCOPE OF DRUG UTILIZATION EVALUATION: 
Drug use evaluation (DUE) or DU studies is a continuous, official and 
logical quality improvement method, which is considered to: 
 Study drug utilization and/or prescribing patterns. 
  Distribute criticism of results to clinicians. 
  Build up standards and criteria which illustrate optimal drug use. 
  Maintain proper drug utilization through education and other interventions.[49] 
  They supply feedback of drug use data to prescribers.  
 They attach the number of patients exposed to the number of cases of adverse 
effects. They assess drug at a population level, according to age, sex, social, 
class. They include concept of appropriateness that must be assessed relative to 
the indication for the treatment, concomitant diseases and the utilization of other 
drugs. 
Thus DUE plays a main role in helping the healthcare system to recognize, 
understand and develop the prescribing, administration and use of medications.[57,58]  
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SOURCES OF DATA ON DRUG UTILIZATION: 
 Large database. [47,59] 
  Data from drug authoritarian agencies.[60] 
 Supplier (distribution) data.[61,62] 
  Practice setting data.[63] 
- Prescribing data. 
- Dispensing data. 
- Aggregate data. 
- Over- the- counter and pharmacist – prescribed drugs. 
 Community setting data. 
 Drug use evaluation.[64] 
BENEFITS OF DRUG UTILIZATION: 
The main principal of DU research is to promote the coherent use of drugs in 
individuals. For the individual patient, the coherent use of a drug indicates the 
prescription of a well recognized drug at an ideal dose, along with the accurate 
information, at an standard price. Without knowledge of the manner of prescribing a 
drug and it use, it is stiff to initiate a discussion on rational drug use or to commend 
measures to promote prescribing habits. DU research affords to rational drug use in 
important ways as described below.  
 DISCRIPTION OF DRUG USE PATTERNS: 
DU research can improve our knowledge in how drugs are used as below. 
 It might be used to determine the numbers of patients disclosed to specific 
drugs within a period. 
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  It can explain the extent of use at an absolute moment and/or in a satisfied 
area (e.g. in a country, region, community or hospital).  
 It can distinguish the prototype or contour of drug use and the scope to which 
substitute drugs are used to cure particular conditions. 
  It may be used to analyze the observed prototype of drug use for the healing 
of a certain disease with current guidelines. 
 EARLY SIGNALS OF IRRATIONAL USE OF DRUGS: 
DU research might create hypotheses that set the agenda for further 
investigations, and thus prevent prolonged illogical use of drugs.  
 INTERVENTIONS TO IMPROVE DRUG USE: 
DU research allows us to evaluate whether interventions intended to enhance 
drug use have had the ambition impact. 
 QUALITY CONTROL OF DRUG USE: 
Drug use supposed to be managed according to a quality control cycle that 
offers a systematic framework for continuous quality improvement.[65]  
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Step1. Plan. Analyze current situation to establish 
a plan for improvement (e.g. analyze current 
prescription patterns of individual prescribers, 
groups of prescribers, or health facilities). 
 
Step 2. Do. Implement the plan on a small scale 
(e.g. provide feedback on possible overuse, 
underuse or drug misuse of individual drugs or 
therapeutic groups). 
Step3. Check to see if expected results are 
obtained (e.g. evaluate whether prescription 
patterns really improve). 
Step 4. Act Revise plan or implement plan on 
large scale (e.g. guide national implementation of 
plan). 
Chapter 2 Literature Review 
 
Dept. of Pharmacy Practice  17 J.K.K. Nattraja College of Pharmacy 
LITRATURE REVIEW 
Steven E. Reis [66] et al., (1997) conducted a study on practice patterns and 
outcome for the treatment of congestive heart failure. This study sought to define 
specialty- related difference in the care and outcome of patients admitted to the 
hospital with congestive heart failure. The study included patients admitted to 
university teaching hospital in US who had been cared by a generalist (n=160) and 
those whose care was guided by a cardiologist (n=138) in a period of 6 months. 
Subject of >50% of patients admitted to the hospital with CHF cared for by 
generalists alone had minimal symptoms compared with <15% of those cared for 
by cardiologist (p < 0.01). the various drugs used frequently were divided into 
3stages, pre-hospital, in hospital and while discharge. In pre-hospital and 
discharge stage ACE-I, Digoxin, Diuretics and Nitrates were prescribed. In 
hospital IV diuretic therapy, IV inotropic therapy and IV vassopressor therapy 
were used. It was concluded that involvement of cardiologist in the care of patients 
admitted to the hospital with CHF is associated with increased use of diagnostic 
testing, longer hospital stays and improved clinical outcome. These results 
substantiate practice guidelines that suggest a role for cardiologists in the care of 
symptomatic patients with CHF. 
Mitu Baskota [67] et al., (2006) conducted a study on the prescribing patterns 
on drugs used in heart failure. The prevalence of heart failure in south Asian 
Origin including Nepal increases with the age and accounts for most of the adult 
hospital admissions. The study included both the in-patients and outpatients 
conducted at 2 different hospitals inside the Kathmandu valley and one outside the 
valley, Dhulikhel. The period of the study was around 4 months and the number of 
patients included was 156, which included total of 71 males (52.59%) and 64 
females (47.4%). Subjects of age groups 45-65 (45%) were found to be more 
susceptible to heart failure. Significant age, smoking & alcohol use, associated 
disease, family history of disease related factors in the prevalence of heart failure 
were seen. The various drugs used frequently were, Diuretics, Cardiac glycosides, 
ACE-I, A II Receptor blockers and Anti-Coagulants. In the combination of drugs 
ACE-I+ Diuretics+ Digoxin was used most frequently. ACE-I was not 
appropriately prescribed as per the literature facts that they various benefits in the 
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treatment of Congestive Heart Failure and hence was underused. Ramipril, 
Lisinopril were also considered in the prescriptions in spite of their new entries. 
ARB though similar in properties to the ACE accounts for a very small proportion 
of drug use profile, where high cost and lower availability may be accounted. 
Beta- blockers were also prescribed extensively. 
CA Richter[68] et al., (2009) conducted a study on practice pattern and 
outcomes in patients presenting to the emergency department with acute heart 
failure. This study sought to describe current treatment patterns of patients 
presented to the emergency department (ED) with acute HF and investigate 
whether these treatments influenced outcomes. A health record review was 
performed in a 30% random sample of all patients who presented to 6 ED in the 
Capital Health Region (Edmonton, Alberta) with a most responsible diagnosis of 
acute HF from April 2002 to March 2003. A total of 448 patients (45% women) 
with a mean (± SD) age of 75.3± 11.2 years were included. Co-morbidities 
included hypertension (55%), coronary artery disease (39%), and previous 
myocardial infarction (38%). In the first 72 h, patients were commonly treated 
with IV furosemide (48%), ACE-I or ARB (45%), oral furosemide (42%) and 
salbutamol (38%). 45% of patients were admitted to the hospital, and 20% died or 
were readmitted within 30 days. Multivariate logistic regression analysis revealed 
age, history of HF, history of angioplasty and oxygen administration in the ED as 
independent predictors of death or readmission at 30 days. No medicines were 
associated with decreased readmission or death. It was concluded hate current 
treatment patterns for acute HF mostly symptomatic. Proven efficacious HF 
therapies remain underused. Future research should focus on the integration of 
disease management, identifying predictors of admission and readmission, and 
treatments to reduce re-hospitalization. 
Tasneem Sandozi [69] et al., (2010) conducted a study on drug utilization for 
ischemic heart disease associated with diabetes and hypertension. The study 
sought to evaluate drug utilization in acute coronary syndrome associated with 
diabetes and hypertension in a tertiary care hospital in Hyderabad, India. It was a 
retrospective study done for a period of 3 months during which treatment of 140 
patients was studied, 96 of these were male and 44 were female. The average age 
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of male was 62 years (range 36-63 years) while for female was 61 years (range 30-
80 years). The average number of drugs prescribed per patient was 9.93 which is 
states that the incidence of poly-pharmacy was high. Trade names were used more 
frequently when compared to generic names. If only generic names are used it can 
decrease the financial burden of the patient. The most frequent drugs prescribed 
were Beta Blockers (Metoprolol), Calcium Channel Blockers (Amlodipine), ACE-
I (Captopril), Lipid Lowering Agents (Atorvastatin), Anticoagulants 
(Unfractionated heparin) and Antiplatelet drugs (Aspirin and Clopidogrel 
combination).the value of long term use of clopidogrel along with aspirin was 
substantial, making this drug a valuable addition to the effective medication for 
secondary prevention of high risk patients. 
MD. Abdul Muhit[70]et al., (2012) conducted a study on cardiovascular 
diseases prevalence and prescription pattern in a tertiary care hospital in 
Bangladesh. A cross- sectional type descriptive study was carried out at the 
outdoor of National Institute of Cardiovascular Diseases (NICVD), Dhaka from 
July’09 to August’ 09. A total of 780 patients, who acquire with the inclusion and 
exclusion criteria, were interviewed with structured questionnaire and followed up 
by prescription monitoring. Out of the total patients with a male, female ratio of 
5.3:4.7, 45.90% patients were over 55 years and 69.62% patients had come from 
urban area. The patients had lipid level disorder (47.05%), hypertension (28.05%), 
heart failure (27.25%), ischaematic heart disease (21.55%) and 40.39% were 
associated with diabetes. Individual patients got 6.35± 1.56 number of drug of 
different class of which most frequently prescribed were antiatherogenic (97.67%), 
lipid lowering agents (95.35%), antianginal (79.07%), beta- blockers (51.16%), 
ACE inhibitors (30.23%), diuretics (37.21%), anxiolytics (81.4%)etc. The data 
may be proportion for the general physicians for optimizing rational use of 
cardiovascular drugs and also accessible in formulating strategy for effective CVD 
management. 
Popuri Rupa Sindhu[71] et al., (2013) conducted a study on prescriptive 
patterns of antihypertensive drugs in south India super-specialty hospital. This 
prospective study was carried out in a period of 4 months from a series of 205 
patients of either sex by scrutinizing the outpatient cards and laboratory reports of 
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inpatients attending the hospital. The data collected were analyzed for prescribing 
patterns of antihypertensive drugs and demographic profiles of the patients 
suffering from hypertension. The results were analyzes and tabulated statistically 
by student’s t test. P value <0.05 is considered. The study revealed that calcium 
channel blockers were the drug of choice for hypertensive patients as a single drug 
therapy and overall utilization. Utilization of diuretics in the study was 5.1% as 
mono therapy which is lesser even though they are available at lower cost. The 
study showed that a higher percentage of patients (56.09%) were found to be on 
dual therapy and among them 73 (63.4%) were found to be treated with fixed dose 
combination i.e. ARB + Diuretics followed by beta blockers + CCBs and the 
reduction of SBP and DBP was found to be significant with these combinations 
and the pattern is according to JNC guidelines. The study revealed that the 
prescription of antihypertensive medication is according to JNC guidelines except 
mono therapy of diuretics. 
A. Sivakumar[72] et al., (2014) conducted a study on prescription pattern of 
anti- hypertensive’s in a tertiary care hospital. In a prospective study of 9 months 
duration prescriptions containing anti-hypertensive’s were collected from the 
patients attending the outpatient department of general medicines. Pregnant 
women were excluded from the study. The patients demographics, blood pressure, 
anti-hypertensive drugs prescribed were entered in a specially designed Performa. 
A total of 310 prescriptions were monitored, of which 188 were male and 122 
were female. The age groups vary from 21 to 70 years. Among 310 hypertensive’s, 
58.38% of patients were treated with dual combinations, 30.64% of patients were 
treated with single anti-hypertensive drug and 10.96% of patients were treated 
with triple drug combinations. In monotherapy, ARB (Telmisartan) were most 
commonly prescribed (n=21). In combination therapy, a two drug combination 
consisting of ARB (Telmisartan) and diuretics (hydrochlorothiazide) were given to 
the majority of patients (n=40; 12-90%). In the triple drug therapy ARB 
(Telmisartan), diuretics (hydrochlorothiazide) and calcium channel blockers 
(Amlodipine) are the highest prescription(8.06%) for the patients. The study 
conclude that, ARBs were the most used anti-hypertensive agents especially 
Telmisartan. ACEIs were the least prescribed anti-hypertensive agent. Double and 
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triple combination therapies are more used when compared to monotherapy. In 
combination ARB and Diuretics (16.23%) were placing the first place in 
prescription and followed by ARB and CCB (12.73%). The least combination was 
Beta Blockers with Diuretics (1.93%). 
Shruti Dawalji[73] et al., (2014) conducted a prospective, observational 
study on prescribing pattern in coronary artery disease in the department of 
cardiology at Global Hospital, Hyderabad in a period of 9 months duration. Pattern 
of different drugs prescribed in coronary artery disease were analyzed. 170 
patients were included in the study. Out of these, 124 (72.94%) were male and 46 
(27.06%) were female patients. Most of the patients diagnosed with coronary 
artery disease were of the age group of 46-66 (72.36%). The most common co-
morbid conditions were hypertension in 110 (64.71%) and diabetes in 66 (38.82%) 
patients. The prescription pattern of various cardiovascular drugs were found to be 
as anti-platelet drugs 169 (99.41%), anti-hyperlipidemic drugs 162 (95.29%), 
antibiotics 158 (92.94%), anti-anginal drugs 137 (80.59%), anti-hypertensives 110 
(64.71%), anti-coagulants 110 (64.71%), diuretics 106 (62.35%) and 
bronchodilators 31 (18.24%). The average number of drugs per prescription was 
found to be 9.68 and the percentage of drugs prescribed by generic name was 
found as 1.76%. The percentage of encounters with an antibiotic prescribed was 
92.94%. The most commonly prescribed drug classes in coronary artery disease 
were anti-platelet drugs followed by anti-hyperlipidemic and antibiotics. This was 
followed by anti-anginal drugs, anti-hypertensives and anti-coagulants. Poly-
pharmacy (9.68 drugs per prescription) was noticed. Very few drugs were 
prescribed by generic name. the prescribing pattern could be improved by reducing 
the number of drugs per prescription and by prescribing generic drugs to reduce 
economic burden of the patients. 
Nikhat Tabassum[74] et al., (2014) conducted a prospective study on drug 
utilization evaluation of cardiovascular drugs to understand the pattern occurrence 
of the various cardiovascular diseases and bring awareness about the rational use 
of drugs. Total 100 patients suffering from different types of cardiovascular 
diseases were included in the study within a time period of 6 months.  As per the 
data collected from the case sheets of 100 patients it can be concluded that average 
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prevalence of cardiovascular diseases were found to be more in males than in 
females. Among the various CVD high prevalence was found to be of 
hypertension. Common age group of CVD was observed as 40-60 years. It was 
concluded that the drugs used for the treatment of cardiac disease are almost found 
to be rational. Rational use of drugs minimizes poly-pharmacy, drug interactions 
and in turn it minimizes the hospital stay. The drugs prescribed were from national 
list of essential medicines. The prescribing habits, route of administration, dosage 
forms were found to be appropriate. 
Anand R. Kalamdani[75] et al., (2014) handled a prospective study of 
prescribing pattern of anti-hypertensive drugs in tertiary care hospital in 
Bangalore. This drug utilization study was intended to find out the preferred drug 
group prescribed either alone or in combination and their adherence to the JNC7 
guidelines. Furthermore the prescription variations as regards to the age, and 
concomitant illness were also analyzed. Drug utilization data were analyzed after 
getting the patients particulars regarding age, sex, drugs, concomitant illness etc. 
in the Performa. After analysis it was found that most frequently prescribed anti-
hypertensive drugs were ARBs (58%), CCBs (50%), Beta blockers (15%), 
Diuretics (14%). 68% received mono-therapy while remaining 32% received 
combination therapy. It was concluded that the prescription pattern was found to 
be partly in accordance with JNC VII guidelines. 
Zafar F[76] et al., (2015) conducted a descriptive study on drug utilization 
pattern in cardiovascular diseases in tertiary care hospital in Pakistan in a time 
period of 3 months. This study intended to determine the drug utilization pattern in 
CVDs. Data collected from 100 patients having different age groups and it was 
assessed to determine the prescribing trends. Results indicated that hypertension 
and ischemic heart disease were mostly diagnosed and mostly diseases were 
treated by giving the drugs in combinations. The use of Beta blockers, Diuretics, 
CCBs, and ACE-I was very common. Also prescribing errors related to dosing 
frequency and prescribed dose were also determined. 
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Bharath Kumar D[77] et al., (2015) carried out a retrospective study on drug 
utilization pattern in patients with congestive cardiac failure in a south Indian 
tertiary care hospital in a time period of 1 year. The study attempted to analyze the 
drug utilization pattern in CCF patients. A total of 100 prescriptions were analyzed 
from medical records of patients admitted to cardiology department with CCF. 
There were 68 male patients and 32 female patients. Most of the patients 83 (83%) 
affected with CCF were above 50 years. Hypertension 43 (25.1462%) was the 
most common co-morbidity seen with CCF. Diuretics 166 (29.80251%) were the 
most common class of drugs used to treat CCF. Under inotropic drugs, Digoxin 79 
(32.6443%) was used in majority of CCF patients as evident from study. The study 
showed that poly-pharmacy 96 (96%) was preferred than mono-therapy 4 (4%) in 
CCF patients. The most common route preferred was Oral route720 (72.28916%) 
than 276 (27.71084%) intravenous route. 
Mukesh Kumar[78] et al., (2016) conducted a  study on cardiovascular 
disease prevalence and drug utilization patterns at a tertiary care hospital in 
northeastern India in a time period of 3 months. 112 patients fulfilled the inclusion 
criteria were included to the study. Case papers were analyzed and documented for 
demographic variables, indications, disease prevalence, co-morbidities and 
prescribing pattern of the physician. It resulted that patients of age 61-90 y 
(48.21%) were diagnosed of CVDs. Male patients (67%) were diagnosed CVDs 
more than female patients (33%). It was indicated that hyperlipidemia (84.82%), 
hypertension (80.35%), and ischemic heart disease (66.96%) were most frequently 
diagnosed diseases and most of the diseases were treated by the combination of 
two or three drugs. The use of statins, beta blockers, diuretics, calcium channel 
blockers and AEC-I was very common. Diabetes, anemia and asthma were the co-
morbidities associated with CVDs. 
Bandla Aswani[79] et al., (2016) carried out a prospective observational 
study on prescribing pattern of cardiovascular drugs and potential drug –drug 
interactions in an inpatient cardiology unit of a cardiac care hospital at Tirupathi, 
India in a time period of 6 months during regular ward rounds. The demographic 
details and treatment data of the 180 patients were collected in a specially 
designed Performa. The average age of study population was found to be 59.06 ± 
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1.8 years. Subjects of age groups > 40 (92.77%) were found to be more susceptible 
to CVD and majority of them were males 46.66%. average number of 
cardiovascular drugs per patients was 5.58. 57.05% of the drugs prescribed were 
from the Indian 2011 list of essential drugs. Poly-pharmacy was observed in 
68.33% (123) prescriptions. The prescription rate of antiplatelet, anticoagulant and 
fibrinolytics were 22.46% followed by 20.07% of antianginal drugs. The 
prescribing frequency of antianginal drugs 88.57% during discharge time was 
more higher. 390 potential drug –drug interactions were screened. Medication 
adherence were more in male patients 56.12% among the 86.66% of follow up 
patients. 
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AIM AND OBJECTIVES 
AIM: 
 To study the prevalence and drug prescription pattern of cardiovascular disease 
in a tertiary care hospital. 
OBJECTIVES: 
 To find out the prevalence of cardiovascular diseases. 
 To study the demographic details of cardiac patients. 
  To study category of drugs prescribed to cardiovascular diseases. 
 To identify the most commonly prescribed drugs for cardiovascular diseases. 
 To assess the prescribing habits of Cardiologists. 
 To promote rational use of drugs. 
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METHODOLOGY 
Study Site 
The study is carried out in outpatient department of cardiology in tertiary 
care hospital, Erode, Tamil Nadu, India. 
Duration of study  
The duration of study is 10 months (July 2016 - February 2017). 
Study design 
It is a retrospective observational study. 
Source of Data 
 Patient’s medication profile. 
 Physicians prescribing records. 
 Nursing charts. 
Parameters for Evaluation 
 Gender distribution. 
 Average age range of patients. 
 Types of cardiovascular diseases found. 
 Associated diseased conditions. 
 Types of drugs mainly used for CVD. 
 Types of other adjuvant drugs used for treatment. 
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STUDY CRITERIA 
Inclusion Criteria 
 Any patients visited the cardiology department during study period. 
 Patients with other co-morbid conditions. 
 Patients in 18 years and above. 
Exclusion Criteria 
 Patients in other departments of the hospital. 
 Pregnant and lactating women. 
 Patients below 18 years. 
 Surgery patients. 
STUDY PROTOCOL 
 Designing a data entry form with all details of patients, medication and 
diagnostic methods. 
 Collecting the case histories of the patients from the medical records. 
 Analyzing the data’s and divides into various categories and concluding it.   
 Prescription analysis has to be performed by the help of medical records.
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TABLES AND GRAPHS 
Table 1. Prevalence of Cardiovascular diseases in study population 
Sl. No 
Total number of patients 
visited the hospital during 
study period 
Number of CVD 
prescriptions 
during study period 
(n) 
Percentage (%) 
1. 5275 500 9.478 
 
Figure 1. Prevalence of Cardiovascular diseases in study population 
Total No. of 
patirnts durng 
study 
CVD , 9.478(%)
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Table 2.  Sex wise Distribution of CVD patients 
 
 
Figure 2.  Sex wise Distribution of CVD patients 
  
Sl. No Sex Number of patients (n=500) Percentage (%) 
1. Male 301 60.2% 
2. Female 199 39.8% 
Male
60.20%
Female
39.80%
Chapter 5   Table and Graph 
 
Dept. of Pharmacy Practice  30 J.K.K. Nattraja College of Pharmacy 
Table 3. Age wise Distribution among CVD patients 
Sl. No Age Number of patients (n=500) Percentage (%) 
1. 18-20 4 0.8% 
2. 21-30 23 4.6% 
3. 31-40 46 9.2% 
4. 41-50 67 13.4% 
5. 51-60 157 31.4% 
6. 61-70 115 23% 
7. 71-80 68 13.6% 
8. 81-90 16 3.2% 
9. 90> 4 0.8% 
 
Figure - 3: Age wise Distribution among CVD patients 
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Table 4. Cardiovascular diseases observed in study population 
Sl. 
No Medical condition 
Number of patients 
(n=871) 
Percentage 
(%) 
1. Hypertention 259 29.73% 
2. Coronary artery disease 173 19.86% 
3. Aortic valve stenosis(mitral valve replacment) 55 6.31% 
4. Cardiac myopathy 57 6.54% 
5. Ischematic heart disease 58 6.65% 
6. Heart failure 52 5.9% 
7. Myocardial infarction 28 3.21% 
8. Dyslipidemia 45 5.16% 
9. Stroke 16 1.83% 
10. Angina 38 4.36% 
11. Rheumatic heart disease 8 0.91% 
12. Arrhythmia 82 9.41% 
 
Figure 4. Cardiovascular diseases observed in study population 
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Table 5. Co-morbid diseases 
Sl. No Medical condition Number of patients (n=500) Percentage (%) 
1. Diabetes mellitus 180 36% 
2. Anemia 5 1% 
3. Asthma 8 1.6% 
4. COPD 5 1% 
5. Renal disorders 18 3.6% 
6. Thyroid disorders 17 3.4% 
7. GI disorders 11 2.2% 
8. Others 35 7% 
9. None 221 44.2% 
 
Figure 5. Co-morbid diseases 
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Table  6. Prescribing Pattern of Physicians 
Sl.No Category of drugs Number of drugs  (n=2741) 
Percentage 
(%) 
 
1. Lipid lowering agents 326 11.89% 
2. Antiplatelets 460 16.78% 
3. Anticoagulants 82 2.99% 
4. Antianginal 301 10.98% 
5. ACE Inhibitors 162 5.91% 
6. ARB 141 5.14% 
7. Alpha Adrenergic blockers 3 0.10% 
8. Beta Adrenergic blockers 149 5.43% 
9. Beta, Alpha Adrenergic receptor blockers 238 8.68% 
10. Calcium Channel blockers 116 4.23% 
11. Anti Arrhythmia 9 0.32% 
12. Anti Heart Faliure 17 0.62% 
13. Vasodilators 16 0.58% 
14. Diuretics 269 9.81% 
15. Antiulcers 150 5.47% 
16. Antidiabetics 133 4.85% 
17. Others 184 6.73% 
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Table 7. Lipid Lowering Agents 
Sl.No 
Lipid  
lowering agents 
Number of  
drugs (n=326) 
Percentage 
(%) 
1. Atorvastatin 325 99.69% 
2. Fenofibrate 1 0.30% 
 
Figure 7. Lipid Lowering Agents 
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Table 8. Anti-platelets 
Sl. No Anti- platelets 
Number of druds 
(n=460) 
Percentage (%) 
1. Aspirin 329 71.52 
2. Clopidogrel 131 28.47 
 
Figure 8. Anti-platelets 
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Table 9. Anticoagulants 
Sl. 
No 
Anticoagulants 
Number of 
drugs (n=82) 
Percentage 
(%) 
1. Warfarin 42 51.21% 
2. Heparin 23 28.04% 
3. Riaroxaban 17 20.73% 
 
Figure 9. Anticoagulants 
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Table 10. Angiotensin Converting Enzyme Inhibitors (ACE-I) 
Sl. 
No. 
ACE Inhibitors Number of drugs (n=162) Percentage (%) 
1. Lisinopril 157 96.91% 
2. Captopril 3 1.85% 
3. Enalapril 2 1.23% 
 
Figure 10. Angiotensin Converting Enzyme Inhibitors (ACE-I) 
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Table 11. Anti-anginal Drugs 
Sl. No Anti-anginal Number of drugs (n=301) Percentage (%) 
1. Isosorbid dinitrate 91 30.23% 
2. Nitroglycerin 155 51.49% 
3. Ivabradine 53 17.60% 
4. Trimetazidine 2 0.66% 
 
Figure 11. Anti-anginal Drugs 
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Table 12. Alpha Adrenergic Receptors 
Sl. No 
Alpha  
Adrenergic receptors 
Number of  
drugs (n=3) 
Percentage 
(%) 
1. Prazocin 1 33.33% 
2. Tamsulosin 2 66.66% 
 
Figure 12. Alpha Adrenergic Receptors 
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Table 13. Beta Adrenergic Blockers 
Sl. No 
Beta 
Adrenergic Blockers 
Number  of 
drugs (n=387) 
Percentage 
(%) 
1. Carvedilol 238 61.49% 
2. Atenolol 137 35.40% 
3. Propranolol 11 2.84% 
4. Sotalol 1 0.25% 
 
Figure 13. Beta Adrenergic Blockers 
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Table 14. Calcium Channel Blockers 
Sl. 
No 
Calcium 
channel blockers 
Number of  
drugs (n=116) 
Percentage 
(%) 
1. Amlodipine 105 90.51% 
2. Diltiazem 7 6.03% 
3. Verapamil 4 3.44% 
 
Figure 14. Calcium Channel Blockers 
 
 
90.51%
6.03%
3.44%
Amlodipine
Diltiazem
Verapamil
Chapter 5   Table and Graph 
Dept. of Pharmacy Practice  43 J.K.K. Nattraja College of Pharmacy 
Table 15. Anti-arrhythmic Drugs 
Sl. 
No 
Anti- 
arrhythmia 
Number of  
drugs (n=9) 
Percentage 
(%) 
1. Amiodarone 3 33.33% 
2. Flecainide 6 66.66% 
 
Figure15. Anti-arrhythmic Drugs 
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Table 16. Anti-Heart Failure Drugs 
Sl. 
No 
Anti  
Heart Faliure 
Number of  
drugs (n=17) 
Percentage  
(%) 
1. Digoxin 15 88.23% 
2. Dopamaine 1 5.88% 
3. Dobutamaine 1 5.88% 
 
Figure -16: Anti-Heart Failure Drugs 
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Table 17. Diuretics 
Sl. No Diuretics 
Number of  
drugs (n=269) 
Percentage 
(%) 
1. Furosemide 143 53.15% 
2. Spironolactone 113 42% 
3. Hydrochlorothiazide 12 4.46% 
4. Mannitol 1 0.37% 
 
Figure 17. Diuretics 
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Table  18. Anti- Ulcer Drugs 
Sl. No Anti Ulcers 
Number of  
drugs (n=154) 
Percentage 
(%) 
1. Omeprazole 114 74.02% 
2. Ranitidine 36 23.37% 
3. Antacid suspension 4 2.59% 
 
Figure 18. Anti- Ulcer Drugs 
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Table – 19: Anti Diabetes 
Sl. No Anti Diabetics 
Number of  
drugs (n=133) 
Percentage 
(%) 
1. Metformin 52 39.09% 
2. Gliclazide 23 17.29% 
3. Glimipride 6 4.51% 
4. Gibenclamide 7 5.26% 
5. Sitagliptin 9 6.76% 
6. Insulin Analogues 36 20.06% 
 
Figure -19: Anti Diabetes 
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RESULTS AND DISCUSSION 
The cross sectional study was conducted on a tertiary care hospital in a time 
period of 10 months (July 2016 – February 2017). The study is mainly observing the 
prevalence, prescribing pattern and the method of treatment used for the treatment of 
several cardiovascular diseases. The patients from other hospital departments or 
below 18 years, pregnant and lactating women are excluded from this study. The 
patients who diagnosed with any CVDs other than the above categories are selected 
for the study. 
The study mainly observed the patients data like age, sex, previous and 
current medical profile and the various class of treatments and its important in the 
treatment. The data were obtained from patients profile medical records. 
During the study period around 5275 patients visited the hospital. From that 500 
were diagnosed as cardiovascular disease patients so, the prevalence of 
cardiovascular disease was found to be 9.478%. 
In this study a total of 500 patients were selected by the inclusion and 
exclusion criteria. Out of the 500 patients selected 301 (60.2%) patients were male 
and the remaining 199 (39.8%) patients were female. The patients were divided in 
different age groups: between18-20 years (0.8%), 21-30 years (4.6%), 31-40 years 
(9.2%), 41-50 years (13.4%), 51-60 years (31.4%), 61-70 years (23%), 51-80 years  
(13.6%), 81-90 years (3.2%) and >90 years (0.8%). 
In this study most of the patients came under the category of male than 
female, it may be due to their daily activities, smoking and alcoholic habits. In a 
study conducted by Md. Abdul Muhit et al. for CVD prevalence and prescription 
patterns observed that most of the patients were male than female. 
Cardiovascular diseases may affect any age of the life but by increasing the 
age the chance for CVD is also increased. In this study the maximum number of 
patients comes under the age 51-60 years followed by 61-70 years of old. That is 
complied with the previous report of drug utilization evaluation of CVD that the 
common age group of CVD observed as 40-60 years. [74] 
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 Extensive diagnosis made by the physician’s revealed different clinical 
conditions prevailing among the patients. Definitely, 29.73% of patients were 
reported to have hypertension whereas 19.86% of patients were diagnosed with 
coronary artery disease. Almost 9.41% of CVD patients were reported with 
arrhythmia. Ischemic heart disease was reported in 6.65% of patients, cardiac 
myopathy in 6.54% of patients, while 6.31% of patients were reported with aortic 
valve stenosis and 5.9% of patients were diagnosed with heart failure. In addition, 
5.16% of CVD patients were reported with dyslipidemia, 4.36% of patients were 
diagnosed with angina, 3.21% of patients were reported with myocardial infarction, 
1.83% of CVD patients were reported with stroke and 0.91% of patients were 
reported with rheumatic heart disease. 
About half of the population was suffering from hypertension, which 
increase the risk of coronary heart disease. One study revealed that hypertension is 
the second leading cardiovascular disease, which is the major cause of other diseases 
such as heart failure, stroke, myocardial infarction and angina pectoris.[80] Other 
population based studies suggest that elevated insulin levels, which often occurs in 
type II diabetes mellitus, is an independent risk factor and co-exist with 
cardiovascular disease. Other cardiovascular risk factors in diabetic individuals 
include abnormalities of lipid metabolism, platelet function, and clotting factors.[81] 
 The physicians also diagnosed several different medical conditions in the 
patients. For example, 36% of CVD patients were diabetic patients. Around 3.6% of 
patients were suffering from renal disorders, 3.4% of patients thyroid disorders. 
Other associated medical conditions included gastro intestinal disorders (2.2%), 
asthma (1.6%), COPD (1%), anemia (1%), plus many others. 
The possibility of cardiovascular diseases in old patients is more than the 
younger, so associated diseases like diabetes mellitus, renal disorders, thyroid 
disorders, anemia, asthma, COPD and GI disorders. In this study the maximum 
number of associated diseases reported was diabetes mellitus. In a study conducted 
by Mukesh Kumar et al. for CVD prevalence and drug utilization patterns reported 
that diabetes, anemia and asthma were the co-morbidities associated with CVDs. 
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 Physicians prescribed several and different pharmacological therapeutic 
classes of drugs. These drugs prescribed to the patients in different groups have been 
categorized. Most of the patients were advised to take anti-platelets (17.37%) 
followed by lipid lowering agents (12.31%), anti-anginal drugs (11.36%) and 
anticoagulants (3.09%). Several anti-hypertensive drugs were prescribed to the 
patients such as beta adrenoreceptor blockers (8.98%), ACE inhibitors (6.11%), 
angiotensin receptor blockers (5.32%), calcium channel blockers (4.38%), alpha 
adrenergic blockers (0.11%), and diuretics (1.01%). The physicians prescribed 
5.66% of anti-ulcer drugs for the patients with or without ulcers. 
 Among the lipid lowering agents, atorvastatin was given to the most of the 
patients (99.69%). Aspirin and clopidogrel were given to (71.52%) and (28.47%) of 
patients respectively for reducing clotting for obtaining synergistic anti-platelet 
effect of the both compounds. Warfarin, heparin and rivaroxaban were prescribed to 
only (51.21%), (28.04%) and (20.73%) patients, respectively. 
 Anti-angina agents such as vasodilators were used commonly. Nitroglycerin 
was prescribed in 51.49% of patients whereas isosorbide dinitrate were prescribed in 
30.23% of  patients. Ivabradine was prescribed in 17.60% of patients for those who 
cannot take beta blockers. 
 Anti-hypertensive agents are predominantly used among the patients. The 
most preferred options were beta blockers, ACE inhibitors and diuretics. Adrenergic 
receptor blockers are given to the patients with hypertension. Most of the physicians 
prescribed carvedilol (61.49%) and atenolol(35.40%). On the other hand some 
physicians prescribed propranolol (2.84%) and sotalol (0.25%). ACE inhibitors had 
a great chance in the prescriptions. Lisinopril was given to the most of the patients 
(96.91%). Diuretics were the third preferred option by the physicians, Furosemide 
(53.15%) and spironolactone (42%).  
The drugs that were mostly prescribed by the specialist doctors (cardiologist 
and heart specialist) will add value for the general practitioners. The study reveals 
that most of the patients with lipid profile disorders should take lipid lowering 
agents. To circumvent this, physicians prescribed worlds mostly prescribed and 
vended drug namely atorvastatin. It decreases the blood LDL cholesterol level 
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effectively with increasing the HDL level. It also reduces the risk of coronary artery 
disease, myocardial infarction and stroke effectively with fewer side effects.[82] 
The patients with coronary artery disease were treated with anti-atherogenic 
agents to prevent clotting at the coronary vessels that may be fatal to them 
ultimately. This type of narrowing blood vessels may cause of sudden myocardial 
infarction or stroke. In order to prevent this, physician prescribed clopidogrel and 
aspirin. Nitroglycerine was the preferred option for the relief of stable and unstable 
angina. It dilates the blood vessels and supply adequate oxygen to the heart within 
few minute. Nitrates were the second choice for this purpose. 
Beta adrenergic receptors include a class of cardiovascular drugs, which are 
used for hypertension. Cardio-protective and anti-hypertensive effects of this class 
of drugs justify much larger use as observed in this study. Beta blockers reduce 
mortality rate when for primary and secondary prevention of myocardial infarction 
and chronic heart insufficiency.[83],[84] Carvredilol and atenolol were the mostly 
prescribed drugs in this study. It’s followed by ACE inhibitors and diuretics. This 
could be explained by widening of indications for their use in hypertension, diabetic 
nephropathy, heart failure, etc. in the last decade ACE inhibitors become almost the 
most important drugs in cardiology, taking into consideration their cardio-protective 
and reno-protective effects. Many clinical studies confirmed reduction in morbidity 
and mortality in patients with acute myocardial infarction and congestive heart 
failure with the use of ACE inhibitors.[84] 
Thiazide diuretics are fundamentals of anti-hypertensive therapy whereas 
loop diuretics or high ceiling diuretics are used as potent anti-hypertensive agents 
when used alone. Combination of furosemide and spironolactone were prescribed in 
order to overcome the side effects (viz. severe hypertension) of the former one. 
Diuretics are recommended as initial mono-therapy in older patients with stage I or 
II of hypertension, or in combination with severe hypertension. 
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CONCLUSION 
 The study concluded that most of the patients included in the study were 
suffering from hypertension and coronary artery disease. These may be due to their 
food habits, smoking, less exercise and poor health hygiene. 
 The prescribing pattern was rational and it follows the standard treatment 
guidelines so, the treatment was effective because of recovery of normal life of 
patient. 
 The maximum number of patients was male; it may be due to smoking and 
alcoholic habits. 
 Analysis divulges that statins and anti-atherogenic agents are dominant 
cardiovascular drugs when compared to others. Beta blockers, ACE inhibitors, 
diuretics are predominant in anti-hypertensive group. 
 The study has some restrains which leads to say it cannot be a standard one 
because it is carried out in one tertiary level hospital, may not accord with the data to 
other generalized hospitals. Beside that the sample size does not reflect the actual 
population and prescription pattern in the whole state or country. 
Under use of calcium channel blockers and angiotensin receptor blockers 
should be changed by undertaking educative interventions to change the prescribing 
practice. 
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